Australian Clinical Labs Limited (ASX:ACL)

Market Cap	592.26M
Revenue (ttm)	728.27M
Net Income (ttm)	30.67M
Shares Out	196.11M
EPS (ttm)	0.15
PE Ratio	19.67
Forward PE	15.75
Dividend	0.12 (3.97%)
Ex-Dividend Date	Mar 27, 2025

Volume	314,220
Average Volume	801,090
Open	3.040
Previous Close	3.020
Day's Range	3.010 - 3.135
52-Week Range	2.140 - 3.855
Beta	1.13
RSI	44.97
Earnings Date	Aug 26, 2025

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offe...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 4,900
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACL

Financial Performance

In 2024, Australian Clinical Labs's revenue was 696.37 million, a decrease of -0.10% compared to the previous year's 697.07 million. Earnings were 23.93 million, a decrease of -33.33%.